Drug
Rituximab Mabthera Rituxan
Rituximab Mabthera Rituxan: highest development phase Post-Market, developed by Roche. 2 trial records tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Roche
Trials
| Drug | Phase | Indication |
|---|---|---|
| rituximab [MabThera/Rituxan] NCT01117129 | Post-Market | Rheumatoid Arthritis |
| rituximab [MabThera/Rituxan] NCT01332994 | Phase 3 | Rheumatoid Arthritis |
Latest
No recent events.
Follow Rituximab Mabthera Rituxan on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.